Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Immunoconjugates × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Gastrointestinal 1 Breast 1

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 123 Lenalidomide 70 Bortezomib 67 Cyclophosphamide 63 Calcium Dobesilate 51 fludarabine 43 pomalidomide 38 daratumumab 36 carfilzomib 30 Melphalan 28 fludarabine phosphate 27 dexamethasone acetate 20 dexamethasone 21-phosphate 20 auricularum 18 Filgrastim 16 Whole-Body Irradiation 14 Biopsy 14 Magnetic Resonance Spectroscopy 13 Vorinostat 12 Specimen Handling 12 venetoclax 11 isatuximab 11 Sirolimus 11 Rituximab 11 Peripheral Blood Stem Cell Transplantation 11 ixazomib 10 belantamab mafodotin 10 Tacrolimus 10 Panobinostat 10 Granulocyte Colony-Stimulating Factor 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03489525 2022-03-28

MEDI2228

MedImmune LLC

Phase 1 Completed

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡